ASCO Annual Meeting | Conference

Zenocutuzumab Demonstrates Clinical Activity in a Variety of NRG1+ Cancers

June 5th 2021

Zenocutuzumab represents a promising novel targeted therapeutic option for patients with NRG1 fusion–positive cancers.

Aumolertinib Prolongs Survival, Duration of Response in NSCLC

June 5th 2021

Treatment with aumolertinib was associated with prolonged survival and duration of response in patients with non–small cell lung cancer.

Triplet Combination Safe, Effective for Relapsed/Refractory DLBCL

June 5th 2021

Patients with relapsed/refractory diffuse large B-cell lymphoma treated with a novel combination of polatuzumab vetodin, rituximab and lenalidomide contributed to an improved overall response and complete response, with 82% remaining in remission at the study’s cutoff date.

Dr. Bonvalot on the Long-Term Safety of NBTXR3 Plus Radiotherapy in Locally Advanced Soft Tissue Sarcoma

June 5th 2021

Sylvie Bonvalot, MD, PhD, HDR, discusses the long-term safety of NBTXR3 plus radiotherapy in patients with locally advanced soft tissue sarcoma who were treated in the phase 2/3 Act.In.Sarc trial.

Allogeneic HCT Plus Reduced Intensity Conditioning With Bortezomib Triplet Is Safe in Multiple Myeloma

June 5th 2021

Allogeneic hematopoietic cell transplantation was safe when used with a reduced-intensity conditioning regimen of bortezomib, fludarabine, and melphalan in patients with high-risk multiple myeloma.

Sotorasib Impresses With Durable Clinical Benefit in KRAS p.G12C+ NSCLC

June 5th 2021

Sotorasib provided continued durable clinical benefit in patients with pretreated KRAS p.G12C–mutated non–small cell lung cancer.

Brexucabtagene Autoleucel Induces High, Durable Responses in Heavily Pretreated Relapsed/Refractory B-ALL

June 5th 2021

A single infusion of brexucabtagene autoleucel, a CAR T-cell therapy, demonstrated robust and durable responses in heavily pretreated patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Amivantamab/Lazertinib Yields Durable Responses in Osimertinib-Relapsed, Chemo-Naïve EGFR+ NSCLC

June 5th 2021

Amivantamab in combination with lazertinib elicited responses in more than one-third of chemotherapy-naïve patients with EGFR-mutant non–small cell lung cancer who had progressed on osimertinib.

Lifileucel/Pembrolizumab Elicits Encouraging ORR in ICI-Naïve Advanced Melanoma

June 4th 2021

The addition of lifileucel to pembrolizumab resulted in an overall response rate of 85.7% compared with pembrolizumab alone in patients with immune checkpoint inhibitor–naïve advanced melanoma.

Afami-cel Elicits Durable Response Rates in Patients With Synovial Sarcoma or MRCLS

June 4th 2021

Encouraging initial durability has been observed with afamitresgene autoleucel in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma, according to data from the phase 2 SPEARHEAD-1 trial.

Patritumab Deruxtecan Displays Durable Efficacy in EGFR TKI–Resistant EGFR+ NSCLC

June 4th 2021

Patritumab deruxtecan was found to induce clinically meaningful, durable efficacy in heavily pretreated patients with EGFR-mutated non–small cell lung cancer who were resistant to EGFR TKIs.

Catequentinib Shows Promise in Treatment of Advanced Synovial Sarcoma

June 4th 2021

Catequentinib improved disease control and progression-free survival in patients with advanced synovial sarcoma compared with dacarbazine.

Dr. Skoulidis on the Results of Subgroup Analyses of the CodeBreaK 100 Trial in KRAS G12C-Mutant NSCLC

June 4th 2021

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the results of subgroup analysis from the phase 2 CodeBreaK 100 trial in patients with KRAS G12C-mutant non–small cell lung cancer.

Ponatinib/Blinatumomab Combo Represents Promising Chemo-Free, HSCT-Sparing Treatment for Ph+ ALL

June 4th 2021

The efficacy demonstrated with combination of ponatinib and blinatumomab represent a potentially promising chemotherapy-free, hematopoietic stem cell transplant–sparing treatment for patients with Philadelphia chromosome–positive acute lymphocytic leukemia.

Dr. Reck on Updated Results of the CheckMate 9LA Trial in Advanced NSCLC

June 4th 2021

Martin Reck, MD, PhD, discusses updated results of the phase 3 CheckMate 9LA study in advanced non–small cell lung cancer.

TNO155 Demonstrates Manageable Safety and Consistent SHP2 Inhibition in Advanced Solid Tumors

June 4th 2021

The investigational SHP2 inhibitor TNO155 demonstrated encouraging safety and tolerability, and consistent evidence of SHP2 inhibition in patients with advanced solid tumors.

Tucatinib Concentrations in CSF Demonstrated in HER2+ Metastatic Breast Cancer

June 4th 2021

Evidence of tucatinib and its predominant metabolite, ONT-993, were detectable in the cerebrospinal fluid of patients with leptomeningeal metastasis HER2+ positive breast cancer marking a first for tucatinib distribution into the CSF seen in this patient population.

Dr. Choueiri on the Efficacy of Post-Nephrectomy, Adjuvant Pembrolizumab in RCC

June 4th 2021

Toni K. Choueiri, MD, discusses the efficacy of pembrolizumab as a post-nephrectomy adjuvant therapy for patients with renal cell carcinoma from the phase 3 KEYNOTE-564 trial.

Nivolumab/Ipilimumab Plus Chemotherapy Shows Durable Benefit in Advanced NSCLC

June 4th 2021

Nivolumab and ipilimumab plus 2 cycles of platinum-based chemotherapy demonstrated durable survival benefit vs chemotherapy alone in patients with advanced non–small cell lung cancer.

CLN-081 Elicits Encouraging Efficacy and Safety in EGFR Exon 20–Positive NSCLC

June 4th 2021

CLN-081 demonstrated promising preliminary antitumor activity and an acceptable safety profile across all doses tested in patients with previously treated non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.